Randomized trial of avelumab-cetuximab-radiotherapy versus SoCs in LA SCCHN (REACH)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
Not yet recruiting No Results Available Drug: Cetuximab|Drug: avelumab|Drug: Cisplatin|Radiation: IMRT Progression free survival|Overall survival|Safety: acute adverse events graded by NCI CTCAE v4.03 All Phase 3 688 Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
Epistemonikos ID: 3bc339fd3c8e0d3e1b53632df178068702188227
First added on: May 20, 2024